OXALO THERAPEUTICS
Oxalo Therapeutics is a Biotechnology Company.
OXALO THERAPEUTICS
Social Links:
Industry:
Biotechnology Clinical Trials Medical Therapeutics
Founded:
2017-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.oxalotherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
2.77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Content Delivery Network Euro Wix Wix Bookings
Similar Organizations
Cerebral Magnetics
Cerebral Magnetics is a Biotechnology Company.
Cygnal Therapeutics
Cygnal Therapeutics is a biotechnology company
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
January Therapeutics
January Therapeutics is a San Diego-based biotechnology company.
Libra Therapeutics
Libra Therapeutics is a biotechnology company.
MOMA Therapeutics
MOMA Therapeutics operates as a biotechnology company.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Xios Therapeutics
Xios Therapeutics is a biotechnology company .
Current Employees Featured
Founder
Investors List
National Science Foundation
National Science Foundation investment in Grant - Oxalo Therapeutics
MassChallenge
MassChallenge investment in Grant - Oxalo Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - Oxalo Therapeutics
The University of Chicago Innovation Fund
The University of Chicago Innovation Fund investment in Grant - Oxalo Therapeutics
Official Site Inspections
http://www.oxalotherapeutics.com Semrush global rank: 5.93 M Semrush visits lastest month: 1.39 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Oxalo Therapeutics"
Our Company - OxaloTherapeutic
Yang Zheng is a co-founder and heads all business efforts of Oxalo Therapeutics. Prior to Oxalo, Mr. Zheng served as the VP of Operations for Seurat Therapeutics (another University of Chicago-spun biotechnology company) as well as the …See details»
Oxalo Therapeutics - Home
PRESERVING LONG-TERM KIDNEY HEALTH Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stonesSee details»
Oxalo Therapeutics - Crunchbase Company Profile & Funding
OFX-514: A peptide-based oral therapeutic designed to stimulate and amplify the natural intestinal oxalate-regulation pathway to remove oxalate from the plasma and urine, targeting primary …See details»
Oxalo Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oxalo Therapeutics, Inc. of Chicago, IL. Get the latest business insights from Dun & Bradstreet.See details»
Polsky Center helps launch biotech company from lab …
Jun 3, 2018 While the New Venture Challenge has a 22-year history, it is only recently that the University’s venture creation and technology licensing operations were brought under one organization. The recent expansion of the Polsky …See details»
Oxalo Therapeutics - PitchBook
Oxalo Therapeutics General Information Description. Developer of a novel drug therapy designed to treat and prevent recurrent kidney stones. The company's therapy is derived from a gut bacterium to prevent and treat kidney stone …See details»
Oxalo Therapeutics - Products, Competitors, Financials, Employees ...
Headquarters Location. 1452 East 53rd Street 2nd Floor. Chicago, Illinois, 60615, United States. 312-906-5342See details»
Contact Us - Oxalo Therapeutics
At Oxalo, we are committed to developing innovative therapies for patients with severe and rare kidney diseases caused by oxalate.See details»
Oxalo Therapeutics, Inc. - VentureRadar
Website: http://www.oxalotherapeutics.com. Develops peptide-based treatments targeting rare renal diseases and aims to prevent the recurrence of kidney stones.See details»
Oxalo Therapeutics - Craft
Oxalo Therapeutics has 5 employees at their 1 location and $2.55 m in total funding,. See insights on Oxalo Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Oxalo Therapeutics - Polsky Center for Entrepreneurship and …
Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stones. University of Chicago assistant professor of medicine Hatim …See details»
Oxalo Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
STTR Phase II:Developing a novel drug delivery system to enable …
Type: Domestic Nonprofit Research Organization Abstract The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is a novel drug …See details»
Oxalo Therapeutics Careers and Employment | Indeed.com
Jan 30, 2024 Find out what works well at Oxalo Therapeutics from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for …See details»
Our Technology - Oxalo Therapeutics
OFX-514: First-in-class peptide-based oral therapeutic Oxalo Therapeutics has demonstrated the powerful therapeutic potential of Of-derived factors through in vivo mice studies that …See details»
U of C startup gets $2.3 million for kidney stone prevention drug
Sep 25, 2018 A University of Chicago biotechnology startup is closer to developing a first-of-its-kind drug to prevent kidney stones thanks to $2.3 million from the National Institutes of Health.See details»
Working at Oxalo Therapeutics - Glassdoor
Glassdoor gives you an inside look at what it's like to work at Oxalo Therapeutics, including salaries, reviews, office photos, and more. This is the Oxalo Therapeutics company profile.See details»
Oxalo Therapeutics - Translation | Halo Blog
Renal Diseases . Oxalo Therapeutics develops peptide factors that stimulate certain elements of the microbiome to reduce the risk of kidney stone formation and other types of renal damage.. …See details»
Disease Targets - Oxalo Therapeutics
Approximately 30M Americans have chronic kidney disease (CKD). Plasma oxalate significantly rises to levels that can exceed 30 µM as kidney function declines, putting a significant number …See details»
Media - Oxalo Therapeutics
Oxalo Therapeutics featured in Edgy Labs, driving research from the lab into the real worldSee details»